Authors
Latest:
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer ModelsAyesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AMLThe prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Latest:
Menin Inhibitors for AML: A Roundtable on the Latest AdvancesJustin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.
Latest:
FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R MyelomaThe FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
Latest:
Dr Cosgrove on T-DXd Treatment in Ovarian CancerCasey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.
Latest:
The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The NetworkTennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.
Latest:
Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCLMuhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.
Latest:
Dr Stokes on Radiation Vs Surgery in HPV+ OPSCCWilliam (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.
Latest:
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and ClassificationChristopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian CancerPaul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.
Latest:
Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal CancerI-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.
Latest:
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPCNeil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Latest:
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComaDrs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.
Latest:
Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian CancerKala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.
Latest:
Seeing Medicine Through the Eye of an ArtistFor many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.
Latest:
Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple MyelomaFrancesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.
Latest:
Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCCJerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.
Latest:
Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCLLori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.
Latest:
Dr Amanam on Currently Available JAK Inhibitors for MyelofibrosisIdoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.
Latest:
Dr Pantin on the Evolving Treatment Paradigm in PNHJeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal ResectionRosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Latest:
Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCLSaurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
Latest:
Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and MoreZarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.
Latest:
Discussion of RESORCE TrialPanelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
Latest:
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for SurvivalSeeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.
.jpg?fit=crop&auto=format)
